PT2607484E - Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne - Google Patents

Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne Download PDF

Info

Publication number
PT2607484E
PT2607484E PT131603383T PT13160338T PT2607484E PT 2607484 E PT2607484 E PT 2607484E PT 131603383 T PT131603383 T PT 131603383T PT 13160338 T PT13160338 T PT 13160338T PT 2607484 E PT2607484 E PT 2607484E
Authority
PT
Portugal
Prior art keywords
exon
mrna
methods
muscular dystrophy
duchenne muscular
Prior art date
Application number
PT131603383T
Other languages
English (en)
Inventor
Boudewijn Van Ommen Garrit-Jan
Johannes Platenburg Gerardus
Johannes De Kimpe Josephus
Christina Theodora Van Deutekom Judith
Aartsma-Rus Annemieke
Original Assignee
Academisch Ziekenhuis Leiden
Biomarin Tech Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40873329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2607484(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/NL2008/050673 external-priority patent/WO2009054725A2/en
Application filed by Academisch Ziekenhuis Leiden, Biomarin Tech Bv filed Critical Academisch Ziekenhuis Leiden
Publication of PT2607484E publication Critical patent/PT2607484E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
PT131603383T 2008-10-27 2009-01-13 Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne PT2607484E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2008/050673 WO2009054725A2 (en) 2007-10-26 2008-10-27 Means and methods for counteracting muscle disorders

Publications (1)

Publication Number Publication Date
PT2607484E true PT2607484E (pt) 2016-03-09

Family

ID=40873329

Family Applications (2)

Application Number Title Priority Date Filing Date
PT131603383T PT2607484E (pt) 2008-10-27 2009-01-13 Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
PT09788160T PT2344637E (pt) 2008-10-27 2009-01-13 Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT09788160T PT2344637E (pt) 2008-10-27 2009-01-13 Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne

Country Status (15)

Country Link
EP (4) EP2607484B1 (pt)
JP (2) JP5786109B2 (pt)
AU (1) AU2009310557B2 (pt)
CA (3) CA2741629C (pt)
CY (1) CY1116305T1 (pt)
DK (2) DK2607484T3 (pt)
ES (2) ES2562658T3 (pt)
HK (1) HK1160169A1 (pt)
HR (1) HRP20160078T1 (pt)
IL (2) IL212508A (pt)
NZ (1) NZ592498A (pt)
PL (1) PL2607484T3 (pt)
PT (2) PT2607484E (pt)
SI (1) SI2607484T1 (pt)
WO (2) WO2010050801A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1766010T1 (sl) 2004-06-28 2011-06-30 Univ Western Australia Protismiselni oligonukleotidi za induciranje preskakovanja eksonov in postopki za njihovo uporabo
USRE48960E1 (en) 2004-06-28 2022-03-08 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
CN101896186A (zh) 2007-10-26 2010-11-24 莱顿教学医院 对抗肌肉病症的方式和方法
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP3133160B1 (en) 2008-10-24 2018-12-12 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
EP2480659A2 (en) * 2009-09-24 2012-08-01 Cellectis Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
BR122023023194A2 (pt) 2009-11-12 2023-12-26 The University Of Western Australia Oligonucleotídeo antissentido, composição e respectivo uso
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
JP2014507143A (ja) * 2011-02-08 2014-03-27 ザ シャーロット−メクレンバーグ ホスピタル オーソリティ ドゥーイング/ビジネス/アズ キャロライナズ ヘルスケア システム アンチセンスオリゴヌクレオチド
CN108588073A (zh) 2011-12-28 2018-09-28 日本新药株式会社 反义核酸
AU2013212758A1 (en) * 2012-01-27 2014-08-14 Biomarin Technologies B.V. RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy
WO2014007620A2 (en) * 2012-07-03 2014-01-09 Prosensa Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
NZ775701A (en) 2013-03-14 2022-08-26 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
EP2968991A2 (en) 2013-03-15 2016-01-20 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy
AU2014317961B2 (en) * 2013-09-05 2020-07-30 Murdoch University Antisense-induced exon2 inclusion in acid alpha-glucosidase
JP6519842B2 (ja) * 2013-10-04 2019-05-29 国立大学法人神戸大学 福山型筋ジストロフィー治療用アンチセンス核酸
TR201901939T4 (tr) 2014-03-12 2019-03-21 Nat Center Neurology & Psychiatry Antisens nükleik asit.
CN106661580B (zh) 2014-06-10 2022-02-15 鹿特丹伊拉斯谟大学医疗中心 用于治疗庞帕病的反义寡核苷酸
LT3351633T (lt) 2015-09-15 2020-08-10 Nippon Shinyaku Co., Ltd. Priešprasmė nukleorūgštis
IL258230B (en) 2015-10-09 2022-09-01 Wave Life Sciences Ltd Oligonucleotide preparations and methods thereof
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
US10597658B2 (en) * 2016-03-02 2020-03-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
CN109414511B (zh) 2016-04-18 2023-05-23 萨勒普塔医疗公司 用于治疗与酸性α-葡糖苷酶基因相关的疾病的反义寡聚物及其使用方法
MA45290A (fr) * 2016-05-04 2019-03-13 Wave Life Sciences Ltd Procédés et compositions d'agents biologiquement actifs
KR20190024977A (ko) 2016-06-30 2019-03-08 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머
JP2019522972A (ja) * 2016-07-05 2019-08-22 バイオマリン テクノロジーズ ベー.フェー. 遺伝性障害の治療のための改善された特徴を有する二環式スキャフォールド部分を含むプレmRNAスプライススイッチング又は調節オリゴヌクレオチド
IL297528A (en) 2016-12-19 2022-12-01 Sarepta Therapeutics Inc Exon-skipping oligomer conjugates for muscular dystrophy
BR112019012651A2 (pt) 2016-12-19 2020-01-28 Sarepta Therapeutics Inc conjugados de oligômero de salto de éxon para distrofia muscular
WO2018118599A1 (en) 2016-12-19 2018-06-28 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP3565577A4 (en) 2017-01-06 2020-10-07 Avidity Biosciences, Inc. NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCTION OF EXON SKIP
GB201711809D0 (en) * 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
EP3687577A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
MA50753A (fr) 2017-10-04 2020-08-12 Avidity Biosciences Inc Compositions d'acide nucléique-polypeptide et utilisations de celles-ci
KR102443358B1 (ko) 2017-12-06 2022-09-14 어비디티 바이오사이언시스 인크. 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
JP2021526796A (ja) * 2018-06-13 2021-10-11 サレプタ セラピューティクス, インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマー
CN112955153A (zh) 2018-08-02 2021-06-11 达因疗法公司 肌肉靶向复合物及其用于治疗肌养蛋白病的用途
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
CN113383078A (zh) * 2018-12-06 2021-09-10 波涛生命科学有限公司 寡核苷酸组合物及其方法
CN114375296A (zh) 2019-06-06 2022-04-19 艾维迪提生物科学公司 核酸多肽组合物及其用途
TW202136511A (zh) * 2019-12-19 2021-10-01 日商日本新藥股份有限公司 能進行外顯子跳讀之反義核酸
WO2021132591A1 (ja) 2019-12-26 2021-07-01 日本新薬株式会社 エクソン50のスキッピングを誘導するアンチセンス核酸
CA3173049A1 (en) 2020-02-28 2021-09-02 Nippon Shinyaku Co., Ltd. Antisense nucleic acid inducing skipping of exon 51
KR20220156867A (ko) 2020-03-19 2022-11-28 어비디티 바이오사이언시스 인크. 안면견갑상완 근이영양증의 치료용 조성물 및 방법
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386239A1 (en) 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Methods for identifying rna binding compounds
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
US6727355B2 (en) * 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
AU2003225410A1 (en) * 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
SI1766010T1 (sl) * 2004-06-28 2011-06-30 Univ Western Australia Protismiselni oligonukleotidi za induciranje preskakovanja eksonov in postopki za njihovo uporabo
NZ563206A (en) * 2005-04-22 2009-09-25 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the binding or SR proteins and by interfering with secondary RNA structure
EP1857548A1 (en) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
CN101896186A (zh) 2007-10-26 2010-11-24 莱顿教学医院 对抗肌肉病症的方式和方法
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
EP3133160B1 (en) * 2008-10-24 2018-12-12 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
US9607308B2 (en) 2011-06-29 2017-03-28 American Express Travel Related Services Company, Inc. Spend based digital ad targeting and measurement

Also Published As

Publication number Publication date
PT2344637E (pt) 2015-03-23
ES2532634T5 (es) 2018-04-30
ES2562658T3 (es) 2016-03-07
IL212509A0 (en) 2011-06-30
IL212508A (en) 2013-11-28
WO2010050802A3 (en) 2010-08-12
DK2344637T3 (en) 2015-02-02
AU2009310558A8 (en) 2015-01-22
ES2532634T3 (es) 2015-03-30
JP2012506697A (ja) 2012-03-22
EP2344637B2 (en) 2018-02-28
EP2344637B1 (en) 2014-12-24
HRP20160078T1 (hr) 2016-04-08
AU2009310557A8 (en) 2011-09-29
CA2741793A1 (en) 2010-05-06
EP3400948A1 (en) 2018-11-14
EP2607484B1 (en) 2016-01-06
CA2741629C (en) 2022-07-05
DK2607484T3 (en) 2016-03-07
EP2349287B1 (en) 2018-08-15
PL2607484T3 (pl) 2016-06-30
DK2344637T4 (en) 2018-04-23
CY1116305T1 (el) 2017-02-08
JP2012506698A (ja) 2012-03-22
AU2009310558B2 (en) 2014-09-04
EP2344637A1 (en) 2011-07-20
WO2010050801A1 (en) 2010-05-06
IL212509A (en) 2016-04-21
CA2741793C (en) 2018-10-30
WO2010050802A2 (en) 2010-05-06
AU2009310558A1 (en) 2010-05-06
HK1160169A1 (en) 2012-08-10
SI2607484T1 (sl) 2016-11-30
CA3017539A1 (en) 2010-05-06
JP5905260B2 (ja) 2016-04-20
JP5786109B2 (ja) 2015-09-30
EP2607484A1 (en) 2013-06-26
IL212508A0 (en) 2011-06-30
CA2741629A1 (en) 2010-05-06
AU2009310557A1 (en) 2010-05-06
NZ592498A (en) 2012-05-25
EP2349287A2 (en) 2011-08-03
EP3400948B1 (en) 2022-11-02
AU2009310557B2 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
IL212508A0 (en) Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna
IL282772B1 (en) A method for efficient exon skipping (44) in Duchenne muscular dystrophy and related measures
HK1185098A1 (zh) 高效跳過裘馨氏肌肉營養不良症前體 外顯子 的方法和工具
IL278833A (en) Antisense compounds for inducing axon termination and preparations containing them for the treatment of muscular dystrophy
HK1149338A1 (en) Methods and apparatus for decreasing power consumption and bus activity
EP2296805A4 (en) PROCESS AND APPARATUS FOR THE MANUFACTURE OF TITANIUM ALUMINUM ALLOYS
ZA201100651B (en) Method for dispersing and separating nanotubes
EP2247950A4 (en) METHODS AND COMPOSITIONS FOR DETECTING MICROORGANISMS
GB0818401D0 (en) Fastener feed method and apparatus
HK1160721A1 (en) Methods and apparatuses for plant aeration
EP2350811A4 (en) METHOD AND APPARATUS FOR MODULE REDUCTION
HK1132307A1 (en) Electroplating device and method for electroplating
EP2190986A4 (en) HYBRIDIZATION METHOD AND APPARATUS
EP2340315A4 (en) COMPOSITIONS AND METHODS FOR DETECTION OF JAK2 NUCLEIC ACID MUTATIONS
GB0823333D0 (en) Apparatus and methods
IL209324A0 (en) Aliskiren monofumarate and processes for preparation thereof
EP2495040A4 (en) AGITATOR DEVICE AND STIRRER HOOKS FOR THE SAME
EP2319247A4 (en) METHODS AND APPARATUS FOR PROCESSING AND DISPLAYING IMAGE
EP2330950A4 (en) LOCKABLE LOCHWORK MOUNTING AND METHOD
TWI368845B (en) Multimedia palying method and apparatus thereof
TWI371971B (en) De-interlacing method and apparatus
TWI347126B (en) Dynamic de-interlacing method and apparatus
GB0713944D0 (en) In-Vessel composting apparatus and method